December 11, 2023: ASH 2023: microbiome-based therapy shows potential in graft-versus-host disease - EPR - MaaT Pharma

To see the article, click here!

Previous PostDecember 18, 2023: Microbiome-based treatment shows potential in graft-versus-host disease - BioPharma reporter
Next PostDecember 11, 2023: MaaT Pharma : dans la maladie aigüe du greffon contre l’hôte, MaaT Pharma annonce des résultats prometteurs - BFM Bourse (French only)

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club